Key Points
Dec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lillys (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisks (NOVOb.CO) popular Wegovy as they belong to the same class of medicines...
The views of the five doctors, all senior physicians practicing obesity medicine at top universities and hospitals, indicate that Novo's drug is not likely to have a significant edge based on its heart benefits, even though it will be years before Lilly produces similar cardiovascular data..
In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%...
They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lillys drug, or if future trial results do not produce similar heart benefits...
Lilly is enrolling for a cardiovascular outcomes trial to examine tirzepatide's impact on heart health in patients without type 2 diabetes with data expected in 2027, and completed enrollment for a similar trial in patients with type 2 diabetes, with data expected in 2024...
You might be interested in
Tirzepatide, another diabetes drug cleared for weight loss in US, yet to get regulator nod in India
20, Nov, 23In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company.
Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
09, Nov, 23U.S. and UK regulators both gave thumbs up to Eli Lilly's weight-loss treatment. The drugs are the most effective treatments for weight loss approved to date. | Health
The FDA Approves Weight Loss Drug Zepbound, a Wegovy and Ozempic Rival
09, Nov, 23Eli Lilly is about to release Zepbound, a new entrant in the superheated competition for blockbuster weight loss drugs.
Novo Nordisk says Wegovy heart benefits due to more than weight loss
11, Nov, 23Novo Nordisk (NOVOb.CO) on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday.
Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
27, Jun, 23Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.
Wegovy reduces risk of heart attacks, strokes, and death by up to 20%, new study finds
08, Aug, 23A large global study found that weight-loss drug Wegovy reduced the risk of major cardiovascular issues. It could prompt insurers to cover the drug.
Eli Lilly: still seeking UK approval on pen for weight-loss drug
09, Nov, 23Eli Lilly (LLY.N) on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product's launch.
The next game-changing weight loss drug just moved closer to FDA approval
27, Apr, 23In a new study, patients on tirzepatide (Mounjaro) lost nearly 16% of their body weight in 16 months.
What to know about Eli Lilly's new obesity drug
08, Nov, 23The U.S. Food and Drug Administration approved Eli Lilly's (LLY.N) keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's (NOVOb.CO) popular weight-loss therapy Wegovy.
Mounjaro: Weight loss drug suppresses appetite, awaits FDA approval
17, Mar, 23Tirzepatide, sold as Mounjaro, is a diabetes medication being considered for use to treat obesity, like the related drug semaglutide.